{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:02:54Z","timestamp":1771542174793,"version":"3.50.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007194","name":"Wenzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["Y2020065"],"award-info":[{"award-number":["Y2020065"]}],"id":[{"id":"10.13039\/501100007194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007835","name":"Wenzhou Medical University","doi-asserted-by":"publisher","award":["KYYW202030"],"award-info":[{"award-number":["KYYW202030"]}],"id":[{"id":"10.13039\/100007835","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014587","name":"Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University","doi-asserted-by":"publisher","award":["2022014"],"award-info":[{"award-number":["2022014"]}],"id":[{"id":"10.13039\/100014587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.961758","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:03:10Z","timestamp":1664517790000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Qian-Ya","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Di","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Shi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Guo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cai-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson's disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20458","article-title":"Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations","volume":"20","author":"Jankovic","year":"2005","journal-title":"Mov Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.26125","article-title":"Clinical spectrum of levodopa-induced complications","volume":"30","author":"Aquino","year":"2015","journal-title":"Mov Disord."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","article-title":"Levodopa-induced dyskinesias","volume":"22","author":"Fabbrini","year":"2007","journal-title":"Mov Disord."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S268","DOI":"10.1007\/s00415-010-5719-9","article-title":"The clinical spectrum of levodopa-induced motor complications","volume":"257","author":"Hametner","year":"2010","journal-title":"J Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/ana.410010211","article-title":"Ocular dyskinesias in patients with Parkinson's disease treated with levodopa","volume":"1","author":"Shimizu","year":"1977","journal-title":"Ann Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1111\/j.1468-1331.2007.01919.x","article-title":"Levodopa-induced ocular dyskinesia in Parkinson's disease","volume":"14","author":"Grotzsch","year":"2007","journal-title":"Eur J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/mds.870130421","article-title":"Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's disease","volume":"13","author":"LeWitt","year":"1998","journal-title":"Mov Disord."},{"key":"B10","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/mds.10017","article-title":"Levodopa-induced ocular dyskinesias in Parkinson's disease","volume":"17","author":"Linazasoro","year":"2002","journal-title":"Mov Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/mds.26934","article-title":"Blepharospasm 40 years later","volume":"32","author":"Defazio","year":"2017","journal-title":"mov disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000341621","article-title":"Prevalence of blepharospasm and apraxia of eyelid opening in patients with parkinsonism, cervical dystonia and essential tremor","volume":"68","author":"Rana","year":"2012","journal-title":"Eur Neurol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3988\/jcn.2005.1.2.159","article-title":"Clinical analysis of blepharospasm and apraxia of eyelid opening in patients with parkinsonism","volume":"1","author":"Yoon","year":"2005","journal-title":"J Clin Neurol."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/122.6.1133","article-title":"From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity","author":"Krack","year":"1999","journal-title":"Brain."},{"key":"B15","unstructured":"Variability in the duration of the onset of idiopathic Parkinson's disease after essential blepharospasm2012\n            QayyumRA\n            AyshaA\n          23605608Acta Med Iran.512013"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1002\/mds.20084","article-title":"Development of Parkinson's disease in patients with blepharospasm","volume":"19","author":"Micheli","year":"2004","journal-title":"Mov Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s004150050347","article-title":"Idiopathic blepharospasm does not lead to a Parkinsonian syndrome: results of a questionnaire-based follow-up study","volume":"246","author":"Soonawala","year":"1999","journal-title":"J Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/WNF.0000000000000316","article-title":"Blepharospasm as a manifestation of peak of dose dyskinesia in Parkinson disease","volume":"42","author":"Ramirez-Gomez","year":"2019","journal-title":"Clin Neuropharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jns.2013.05.022","article-title":"Secondary blepharospasm associated with structural lesions of the brain","volume":"331","author":"Khooshnoodi","year":"2013","journal-title":"J Neurol Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.parkreldis.2020.06.034","article-title":"Basal ganglia and cerebellar circuits have distinct roles in blepharospasm","volume":"78","author":"Glickman","year":"2020","journal-title":"Parkinsonism Relat Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1523\/JNEUROSCI.3634-15.2016","article-title":"The cerebral network of parkinson's tremor: an effective connectivity fmri study","volume":"36","author":"Dirkx","year":"2016","journal-title":"J Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1093\/brain\/awv096","article-title":"Abnormal dopaminergic modulation of striato-cortical networks underlies levodopa-induced dyskinesias in humans","volume":"138","author":"Herz","year":"2015","journal-title":"Brain."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1212\/WNL.0000000000002560","article-title":"Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development subcommittee of the American Academy of Neurology","volume":"86","author":"Simpson","year":"2016","journal-title":"Neurology."},{"key":"B24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/PL00007813","article-title":"Botulinum Toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm","volume":"248","author":"Jost","year":"2001","journal-title":"J Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/mds.870030107","article-title":"Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs","volume":"3","author":"Greene","year":"1988","journal-title":"Mov Disord."},{"key":"B26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2165\/00003495-200464030-00002","article-title":"Primary blepharospasm: diagnosis and management","volume":"64","author":"Defazio","year":"2004","journal-title":"Drugs."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","article-title":"International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease","volume":"33","author":"Fox","year":"2018","journal-title":"Mov Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.961758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T06:03:15Z","timestamp":1664517795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.961758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":27,"alternative-id":["10.3389\/fneur.2022.961758"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.961758","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"article-number":"961758"}}